To explore whether mono- or combination therapies altered the expression of glycolytic enzymes in LKB1−/−NIC mammary tumors, we analyzed expression of HEX2, LDH and PDH in whole tumors harvested from mice that had been treated with AZD8055, 2-DG, combination treatment and Vehicle for 21 days (Fig. 5C), by western blot analysis. This evidence concerns the gene PDP1 and breast cancer.